On January 1, 2016, the appointment of Frank Luppino as Anika Therapeutics Inc.'s Chief Operating Officer has ended, as planned. Moving forward, Mr. Luppino will continue to serve as a consultant to Anika Therapeutics Inc. on an as-needed basis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.36 USD | -2.57% |
|
-1.13% | +11.92% |
07-01 | Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell 3000E Growth Index | CI |
07-01 | Anika Therapeutics, Inc.(NasdaqGS:ANIK) added to Russell 2500 Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.92% | 387M | |
+2.88% | 93.97B | |
+6.58% | 41.61B | |
-13.20% | 33.32B | |
+77.12% | 28.8B | |
-16.02% | 15.61B | |
-8.17% | 13.27B | |
-12.49% | 11.46B | |
+162.44% | 10.06B | |
-54.92% | 9.09B |
- Stock Market
- Equities
- ANIK Stock
- News Anika Therapeutics, Inc.
- Anika Therapeutics Inc. Announces Resignation of Frank Luppino as Chief Operating Officer